|This Slide: #75 of 100|
Slide #75. Columbia Laboratories — Molecular Profiles Ltd.
Columbia Laboratories (CBRX)
Molecular Profiles Ltd.
Columbia Laboratories Inc. (NasdaqCM:CBRX) ["Columbia", the "Company"] has acquired Molecular Profiles Ltd. ["Molecular Profiles"], a privately-held, cash-flow positive, U.K.-based pharmaceutical development services company, for total consideration of approximately $25.0 million comprising $16.7 million in cash and 1,051,323 shares of Columbia common stock, representing ten to eleven times Molecular Profiles' projected EBITDA1 for its fiscal year ending July 31, 2014. The newly issued shares are subject to a twelve-month lock-up period. Excluding transaction costs, the acquisition is expected to be immediately accretive. Additionally, Columbia expects to realize a double-digit impact to its EBITDA1 and operational synergies of up to $400,000 annually. This acquisition was unanimously approved by the Boards of Directors of both companies and received the approval of Molecular Profiles' shareholders. No further approvals are anticipated to be required. In addition, Molecular Profiles' CEO and co-founder, Dr. Nikin Patel, will join Columbia's Board of Directors.
Juniper Pharmaceuticals is engaged in in the business of developing, licensing, manufacturing and selling to its marketing partners pharmaceutical products that utilize its drug delivery technologies to treat various medical conditions. Co.'s products include bioadhesive vaginal gel products for infertility, pregnancy support, amenorrhea, and other women's health conditions, and a bioadhesive buccal system for male hypogonadism. Co. has partnered or sold each of these products for commercialization in various regions of the world. All of the products Co. has developed utilize its Bioadhesive Delivery System, which consists principally of a polymer (polycarbophil) and an active ingredient.
Open the CBRX Page at The Online Investor »
Free CBRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (3.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite